Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma
Vincent Poon(Albert Einstein College of Medicine), Richard Görlick(The University of Texas MD Anderson Cancer Center), Michael Roth(The University of Texas MD Anderson Cancer Center), David S. Geller(Albert Einstein College of Medicine), Sajida Piperdi(Albert Einstein College of Medicine), Erin R. Rudzinski(Indiana University School of Medicine), Douglas S. Hawkins(Seattle Children's Hospital), Jonathan Gill(Albert Einstein College of Medicine)
Cited by 64
Related Papers
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
|Scientific Reports|2016|263